Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 9, 2026

Snowflake stock gets a bold AI call from Wall Street

View original at finance.yahoo.com
Snowflake stock gets a bold AI call from Wall Street Snowflake (SNOW) wants to convince Wall Street its next act is larger than cloud data storage…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Enterprises will need Snowflake's platform before AI can go from demos to the day-to-day activities of corporations

    60% confidence

  • Snowflake's full-year fiscal 2027 product revenue is projected at $5.84 billion, representing 31% growth

    60% confidence

  • Snowflake has 779 clients with trailing 12-month product revenue greater than $1 million

    60% confidence

  • Snowflake has a Buy rating with a $300 price target, implying approximately 22.5% upside from the June 2 closing price of $244.82

    60% confidence

  • Snowflake aims to be seen by investors as one of the primary platforms big firms will use to organise, regulate and activate their data for AI agents

    60% confidence

  • Snowflake struck a five-year, $6 billion deal with Amazon Web Services for AI infrastructure, Graviton processors, product integrations and business AI workload migrations

    60% confidence

Data points we hold from this source

Snowflake Inc. · stock price244.82 USD
Snowflake Inc. · backlog9.21 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com